This analysis indicated that the major impact of low dose ribavirin was in thalassemia major patients with older than 24 years of age, a low serum ferritin (< 2006 ng/mL), a previous treatment failure, an elevated ALT and liver fibrosis of 0-4 HAI, history of splenectomy and viral load ≤ 600,000 IU/mL and HCV genotype 1. Here, GPT is linked to thalassemia.